Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01997840 · ClinicalTrials.gov registry record · Phase 1
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
NCT01997840 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 103 participants.
The verdict
NCT01997840, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
Study Summary
Phase 1b: To evaluate the side effects and determine the best dose of ACY-1215 in combination with Pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma. Phase 2: To determine the overall response rate of ACY-1215 in combination with Pomolidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma
Interventions
- DRUG ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2014-03-01 |
| Est. Completion | 2024-02-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01997840
The ClinicalTrials.gov registry entry for NCT01997840 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone is the first listed.
NCT01997840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01997840 about?
NCT01997840 is a clinical study titled "ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma". Phase 1b: To evaluate the side effects and determine the best dose of ACY-1215 in combination with Pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma. Phase 2: To determine the overall response rate of ACY-1215 in combination with Pomolidomide and low-...
What is the current status of trial NCT01997840?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2014-03-01. Estimated completion is 2024-02-29.
What interventions are being tested in trial NCT01997840?
The interventions under investigation include: ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone (DRUG).
Who is sponsoring clinical trial NCT01997840?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.